These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27574424)

  • 1. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
    Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
    Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer.
    Wang Y; Lan M; Shen D; Fang K; Zhu L; Liu Y; Hao L; Li P
    Int J Nanomedicine; 2020; 15():4289-4309. PubMed ID: 32606678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.
    Fan X; Wang L; Guo Y; Tu Z; Li L; Tong H; Xu Y; Li R; Fang K
    PLoS One; 2015; 10(6):e0127419. PubMed ID: 26111008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized Anti-Prostate-Specific Membrane Antigen Single-Chain Variable Fragment-Loaded Nanobubbles as a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer.
    Ding Y; Cao Q; Qian S; Chen X; Xu Y; Chen J; Shen H
    J Ultrasound Med; 2020 Apr; 39(4):761-773. PubMed ID: 31702068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors.
    Zhu L; Wang L; Liu Y; Xu D; Fang K; Guo Y
    Int J Nanomedicine; 2018; 13():6481-6495. PubMed ID: 30410333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
    J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of Nucleolin-Targeted Lipid Nanobubbles and Contrast-Enhanced Ultrasound Molecular Imaging in Triple-Negative Breast Cancer.
    Fang K; Wang L; Huang H; Lan M; Shen D; Dong S; Guo Y
    Pharm Res; 2020 Jul; 37(7):145. PubMed ID: 32666304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
    Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
    Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
    Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
    Kim D; Jeong YY; Jon S
    ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
    Taylor RM; Sillerud LO
    Int J Nanomedicine; 2012; 7():4341-52. PubMed ID: 22915856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer.
    Wang L; Li L; Guo Y; Tong H; Fan X; Ding J; Huang H
    Prostate; 2013 Aug; 73(11):1147-58. PubMed ID: 23532872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
    Leach JC; Wang A; Ye K; Jin S
    Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
    Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
    Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.